Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenues:
Revenues	$ 69,155	$ 52,166
Cost and expenses:
Cost of revenues, excluding amortization of acquired intangible assets	2,607	531
Research and development	36,505	33,702
Selling, general and administrative	61,923	55,604
Amortization of acquired intangible assets	3,476	420
Loss on fair value remeasurement of contingent consideration	512	1,614
Total cost and expenses	105,023	91,871
Loss from operations	(35,868)	(39,705)
Other (expense) income:
Interest expense	(9,273)	(8,983)
Interest and investment income	681	395
Gain (loss) on derivatives	1,316	(2,199)
Loss on extinguishment of debt		(2,009)
Other expense, net	(7,276)	(12,796)
Net loss	$ (43,144)	$ (52,501)
Net loss per share—basic and diluted	$ (0.29)	$ (0.36)
Weighted average number of common shares used in net loss per share—basic and diluted:	151,013	147,786
Collaborative arrangements
Revenues:
Revenues	$ 63,086	$ 51,865
Product
Revenues:
Revenues	635	289
Active pharmaceutical ingredient
Revenues:
Revenues	$ 5,434	$ 12